{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T00:02:09Z","timestamp":1794614529540,"version":"4.9.1"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:00:00Z","timestamp":1785196800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:00:00Z","timestamp":1792713600000},"content-version":"vor","delay-in-days":87,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hered Cancer Clin Pract"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Prostate cancer with\n                      <jats:italic>BRCA2<\/jats:italic>\n                      mutations has shown sensitivity to poly (ADP-ribose) polymerase (PARP) inhibitors such as olaparib. However, acquired resistance remains a clinical concern. One potential mechanism of resistance is the emergence of reversion mutations that restore the function of BRCA2. Although this mechanism has been observed in other tumor types, only a limited number of clinical reports have described this phenomenon in prostate cancer. This case series highlights three patients in whom\n                      <jats:italic>BRCA2<\/jats:italic>\n                      reversion mutations were detected following disease progression on olaparib.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>\n                      We present three male patients diagnosed with metastatic castration-resistant prostate cancer, each carrying a germline\n                      <jats:italic>BRCA2<\/jats:italic>\n                      mutation. All patients initially responded to olaparib, with a reduction in prostate-specific antigen levels and radiographic disease control. However, after approximately one year of treatment, each patient developed disease progression. Circulating tumor DNA analysis using a commercial liquid biopsy platform was performed after progression. In all cases, additional\n                      <jats:italic>BRCA2<\/jats:italic>\n                      mutations were detected, including multiple variants predicted to restore the disrupted open reading frame of the\n                      <jats:italic>BRCA2<\/jats:italic>\n                      gene. These findings were consistent with reversion mutations potentially restoring BRCA2 protein function and thereby conferring resistance to the PARP inhibitor. One patient additionally developed neuroendocrine differentiation during disease progression, highlighting the complexity of resistance evolution.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      This case series provides clinical evidence that\n                      <jats:italic>BRCA2<\/jats:italic>\n                      reversion mutations may underlie acquired resistance to olaparib in prostate cancer. These observations support the utility of liquid biopsy for detecting molecular mechanisms of resistance and suggest that reversion mutations may serve as a biomarker of treatment failure. Understanding such resistance mechanisms is essential for optimizing treatment sequencing and developing novel therapeutic strategies in\n                      <jats:italic>BRCA2<\/jats:italic>\n                      -mutated prostate cancer.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13053-026-00346-x","type":"journal-article","created":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T17:55:42Z","timestamp":1785261342000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["BRCA2 reversion mutations as a resistance mechanism to olaparib in patients with BRCA2-mutated mCRPC: a case series"],"prefix":"10.1186","volume":"24","author":[{"given":"Kohji","family":"Takemura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayumi","family":"Abe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazushige","family":"Sakaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinji","family":"Urakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masami","family":"Arai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7091-628X","authenticated-orcid":false,"given":"Yuji","family":"Miura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,28]]},"reference":[{"key":"346_CR1","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1038\/nrc.2016.72","volume":"16","author":"FC Nielsen","year":"2016","unstructured":"Nielsen FC, van Overeem Hansen T, Sorensen CS. Hereditary breast and ovarian cancer: new genes in confined pathways. Nat Rev Cancer. 2016;16:599\u2013612.","journal-title":"Nat Rev Cancer"},{"key":"346_CR2","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1126\/science.aam7344","volume":"355","author":"CJ Lord","year":"2017","unstructured":"Lord CJ, Ashworth A. PARP inhibitors: Synthetic lethality in the clinic. Science. 2017;355:1152\u20138.","journal-title":"Science"},{"key":"346_CR3","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1038\/nature06548","volume":"451","author":"SL Edwards","year":"2008","unstructured":"Edwards SL, Brough R, Lord CJ, Natrajan R, Vatcheva R, Levine DA, et al. Resistance to therapy caused by intragenic deletion in BRCA2. Nature. 2008;451:1111\u20135.","journal-title":"Nature"},{"key":"346_CR4","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1038\/nature06633","volume":"451","author":"W Sakai","year":"2008","unstructured":"Sakai W, Swisher EM, Karlan BY, Agarwal MK, Higgins J, Friedman C, et al. Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature. 2008;451:1116\u201320.","journal-title":"Nature"},{"key":"346_CR5","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1126\/science.1252230","volume":"343","author":"AR Venkitaraman","year":"2014","unstructured":"Venkitaraman AR. Cancer suppression by the chromosome custodians, BRCA1 and BRCA2. Science. 2014;343:1470\u20135.","journal-title":"Science"},{"key":"346_CR6","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1038\/nature03445","volume":"434","author":"H Farmer","year":"2005","unstructured":"Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005;434:917\u201321.","journal-title":"Nature"},{"key":"346_CR7","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","volume":"382","author":"J de Bono","year":"2020","unstructured":"de Bono J, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, et al. Olaparib for metastatic castration-resistant prostate cancer. N Engl J Med. 2020;382:2091\u2013102.","journal-title":"N Engl J Med"},{"key":"346_CR8","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1056\/NEJMoa2214676","volume":"388","author":"K Fizazi","year":"2023","unstructured":"Fizazi K, Piulats JM, Reaume MN, Ostler P, McDermott R, Gingerich JR, et al. Rucaparib or Physician\u2019s Choice in Metastatic Prostate Cancer. N Engl J Med. 2023;388:719\u201332.","journal-title":"N Engl J Med"},{"issue":"44","key":"346_CR9","doi-asserted-by":"publisher","first-page":"17079","DOI":"10.1073\/pnas.0806092105","volume":"105","author":"S Rottenberg","year":"2008","unstructured":"Rottenberg S, Jaspers JE, Kersbergen A, van der Burg E, Nygren AO, Zander SA, et al. High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 is modulated by P-glycoprotein activity. Proc Natl Acad Sci U S A. 2008;105(44):17079\u201384.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"346_CR10","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1158\/2159-8290.CD-12-0049","volume":"3","author":"JE Jaspers","year":"2013","unstructured":"Jaspers JE, Kersbergen A, Boon U, Sol W, van Deemter L, Zander SA, et al. Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors. Cancer Discov. 2013;3:68\u201381.","journal-title":"Cancer Discov"},{"key":"346_CR11","doi-asserted-by":"publisher","first-page":"3008","DOI":"10.1200\/JCO.2010.34.2980","volume":"29","author":"B Norquist","year":"2011","unstructured":"Norquist B, Wurz KA, Pennil CC, Garcia R, Gross J, Sakai W, et al. Secondary somatic mutations restoring BRCA1\/2 predict chemotherapy resistance in hereditary ovarian carcinomas. J Clin Oncol. 2011;29:3008\u201315.","journal-title":"J Clin Oncol"},{"issue":"9","key":"346_CR12","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1158\/2159-8290.CD-17-0261","volume":"7","author":"J Goodall","year":"2017","unstructured":"Goodall J, Mateo J, Yuan W, Mossop H, Porta N, Miranda S, et al. Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition. Cancer Discov. 2017;7(9):1006\u201317.","journal-title":"Cancer Discov"},{"key":"346_CR13","doi-asserted-by":"publisher","unstructured":"Carneiro BA, Collier KA, Nagy RJ, Pamarthy S, Sagar V, Fairclough S, et al. Acquired resistance to poly (ADP-ribose) polymerase inhibitor olaparib in BRCA2-associated prostate cancer resulting from biallelic BRCA2 reversion mutations restores both germline and somatic loss-of-function mutations. JCO Precis Oncol. 2018;2. https:\/\/doi.org\/10.1200\/PO.17.00176. Epub 2018 Feb 14.","DOI":"10.1200\/PO.17.00176"},{"issue":"9","key":"346_CR14","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1158\/2159-8290.CD-17-0146","volume":"7","author":"D Quigley","year":"2017","unstructured":"Quigley D, Alumkal JJ, Wyatt AW, Kothari V, Foye A, Lloyd P, et al. Analysis of circulating cell-free DNA identifies multiclonal heterogeneity of BRCA2 reversion mutations associated with resistance to PARP inhibitors. Cancer Discov. 2017;7(9):999\u20131005.","journal-title":"Cancer Discov"},{"key":"346_CR15","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1186\/s12885-020-6657-2","volume":"20","author":"AD Simmons","year":"2020","unstructured":"Simmons AD, Nguyen M, Pintus E. Polyclonal BRCA2 mutations following carboplatin treatment confer resistance to the PARP inhibitor rucaparib in a patient with mCRPC: a case report. BMC Cancer. 2020;20:215.","journal-title":"BMC Cancer"},{"key":"346_CR16","first-page":"100480","volume":"29","author":"TR McFarland","year":"2021","unstructured":"McFarland TR, Tandar CE, Agarwal N, Swami U. Emergence of polyclonal BRCA2 reversions following PARP inhibitor treatment: An illustrative case report. Cancer Treat Res Commun. 2021;29:100480.","journal-title":"Cancer Treat Res Commun"},{"key":"346_CR17","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1016\/j.ccell.2024.10.015","volume":"42","author":"G Seed","year":"2024","unstructured":"Seed G, Beije N, Yuan W, Bertan C, Goodall J, Lundberg A, et al. Elucidating acquired PARP inhibitor resistance in advanced prostate cancer. Cancer Cell. 2024;42:2113\u2013e21234.","journal-title":"Cancer Cell"},{"key":"346_CR18","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.eururo.2022.09.010","volume":"83","author":"A Loehr","year":"2023","unstructured":"Loehr A, Hussain A, Patnaik A, Bryce AH, Castellano D, Font A, et al. Emergence of BRCA reversion mutations in patients with metastatic castration-resistant prostate cancer after treatment with rucaparib. Eur Urol. 2023;83:200\u20139.","journal-title":"Eur Urol"},{"key":"346_CR19","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1158\/1078-0432.CCR-22-0931","volume":"29","author":"KN Chi","year":"2023","unstructured":"Chi KN, Barnicle A, Sibilla C, Lai Z, Corcoran C, Barrett JC, et al. Detection of BRCA1, BRCA2, and ATM alterations in matched tumor tissue and circulating tumor DNA in patients with prostate cancer screened in PROfound. Clin Cancer Res. 2023;29:81\u201391.","journal-title":"Clin Cancer Res"}],"container-title":["Hereditary Cancer in Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13053-026-00346-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13053-026-00346-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13053-026-00346-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:02:03Z","timestamp":1792785723000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13053-026-00346-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,28]]},"references-count":19,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["346"],"URL":"https:\/\/doi.org\/10.1186\/s13053-026-00346-x","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-8249251\/v1","asserted-by":"object"}]},"ISSN":["1897-4287"],"issn-type":[{"value":"1897-4287","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,28]]},"assertion":[{"value":"1 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was conducted in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki declaration and its later amendments. Ethics approval was obtained from the Institutional Review Board of Toranomon Hospital (approval no.1879). Written informed consent was obtained from each patient for participation and publication of the case details.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent for publication of this case report, including clinical details and accompanying images, was obtained directly from each patient using the standard consent form of our institution.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"23"}}